Table 4.
Overview of the literature on BM and SRE in SCLC.
| Denmark (Cetin K et al., 2014) | Japan (Katakami N et al., 2014) | Switzerland | |
|---|---|---|---|
| Trial Design | Retrospective, population-based | Prospective, observational | Retrospective, observational |
| duration | 1999-2010 | 2008-2009 | 2000-2010 |
| cancer type | NSCLC and SCLC | NSCLC and SCLC | SCLC |
| n | 5900 (SCLC only) | 77 (SCLC only) | 92 (SCLC only) |
| LD: n.n. | LD: 30 | LD:22 | |
| ED: n.n. | ED: 47 | ED:70 | |
| Median age | 68 years (15.7-104.3) | 68 years (35-89) | 62.7 [39.7 - 81.9] |
| Male sex | 57% | 70.4% | 62% |
| BM incidence | Overall: 16.7% | At first diagnosis: 40.4% | At first diagnosis: 36.9% |
| time to BM from first diagnosis | Overall: 5.1%/year | Overall: 19 months | LD: 14.8 months ED: 0.9 months |
| SRE incidence | Overall: 14.8% | Overall: 18.2% | Overall: 18.4% |
| 50% of all BM patients | -- | 90% of all BM patients | |
| At first diagnosis: -- | At first diagnosis: 8.5% | At first diagnosis: 8.7% | |
| SRE type | Overall (NSCLC+SCLC): | Overall (NSCLC + SCLC): | Overall (SCLC only) |
| Pathologic fracture: 8% | Pathologic fracture: 4.7% | Pathologic fracture: 3.3% | |
| Radiation to bone: 67% | Radiation to bone: 15.7% | Radiation to bone: 10.9% | |
| Surgery to bone: 4% | Surgery to bone: 0% | Surgery to bone: 2.2% | |
| Spinal cord compression: 21% | Spinal cord compression: 1.1% | Spinal cord compression: 1.2% | |
| HCM: -- | HCM: 2.2% | HCM: 4.3% | |
| time to SRE from first diagnosis | 48.2% per year | Overall: 9.5 month | -- |
| Bisphos-phonate use | -- | SCLC overall: 7.8% | SCLC overall: 19.6% |
| LD: 8.5% | LD: 4.5% | ||
| ED: 6.7% | ED: 24.3% | ||
| predictive factors for BM | -- | - ED (HR=6.11; 95% CI 1.69-22.05, p=0.006 | - age ≥ 75 (OR 0.27 (0.10; 0.72), p=0.009 |
| - LDH >1000 at baseline (HR=9.14; 95% CI 1.51-55.14, p=0.016 | - LDH ≥ 300 (OR 3.75 (1.46; 9.63), p=0.06 | ||
| - PTHrP elevation at baseline (HR=0.38; 95% CI, 0.15-0.99, p=0.048 | - LDH ≥ 1000 (OR 5.63 (1.02; 31.07), p=0.05 |